Comparative Pharmacology
Head-to-head clinical analysis: METRA versus METRO I V IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRA versus METRO I V IN PLASTIC CONTAINER.
METRA vs METRO I.V. IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Adults: 20 mg orally once daily.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
None Documented
None Documented
Clinical Note
moderatePhenmetrazine + Atomoxetine
"Phenmetrazine may increase the hypertensive activities of Atomoxetine."
Clinical Note
moderatePhenmetrazine + Iobenguane
"The therapeutic efficacy of Iobenguane can be decreased when used in combination with Phenmetrazine."
Clinical Note
moderatePhenmetrazine + Acebutolol
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol."
Clinical Note
moderatePhenmetrazine + Isoxsuprine
Terminal elimination half-life: 3-7 hours (mean 4.5 hours). Increased to 8-15 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Primarily renal: 70-80% unchanged drug via glomerular filtration and active tubular secretion; 15-20% biliary/fecal as metabolites.
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)
"The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Isoxsuprine."